Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991